Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL1-C52H9 | Cynomolgus | Cynomolgus IL-21 Protein, His Tag | ![]() |
||
IL1-H5213 | Human | Human IL-21 Protein, Tag Free, low endotoxin (HPLC verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
IL1-H5253 | Human | Human IL-21 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
IL1-H82F7 | Human | Biotinylated Human IL-21 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Human IL-21, Tag Free (Cat. No. IL1-H5213) immobilized on CM5 Chip can bind Human IL-21 R, Fc Tag (Cat. No. ILR-H5257) with an affinity constant of 0.412 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NN-9828 | NN-8828; NN-9828; Anti-IL21; NNC114-0005; NNC0114-0006; NNC-0114-0000-0005 | Phase 1 Clinical | Bristol-Myers Squibb Company | Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Inflammation; Crohn Disease; Diabetes Mellitus | Details |
IL-21 mab (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Immune System Diseases | Details | |
Avizakimab | BOS-161721 | Phase 2 Clinical | Medimmune, Boston Pharmaceuticals | Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
BNZ-2 | BNZ-2 | Phase 1 Clinical | Bioniz | Celiac Disease | Details |
This web search service is supported by Google Inc.